Tibet Qizheng Tibetan Medicine Co., Ltd. (hereinafter referred to as Qizheng Tibetan Medicine) is a leading domestic Tibetan medicine enterprise, mainly engaged in the research, development, production and sales of new Tibetan medicines. It now has wholly-owned and controlled subsidiaries such as GMP Pharmaceutical Factory and GSP Marketing Company. 21 companies, with 2,974 employees, and their products cover skeletal muscle system, nervous system, digestive system, cardiovascular and cerebrovascular system, respiratory system, urinary system, gynecology, dermatology, pediatrics and other fields. Among them, the series of topical pain relief drugs represented by Qizheng Xiaopu Patch has been sold at home and abroad, with high clinical efficiency and sales are at the forefront of the Chinese market for topical pain relief drugs.

Qizheng Tibetan Medicine settled in Linzhi, Tibet in 1995. It takes the thousand-year modern inheritance of Tibetan medicine as its mission, and drives the innovation and upgrading of the traditional Tibetan medicine industry through cultural inheritance and scientific and technological innovation. The company has been recognized as the first batch of national innovative enterprises, national high-tech enterprises, national technological innovation demonstration enterprises, national torch plan key high-tech enterprises, and national enterprise technology center. It has two national and local joint laboratories and has successively implemented the national " Key projects of the 11th Five-Year Plan for Science and Technology Support Plan and undertake major national science and technology projects of the 12th Five-Year Plan and the 13th Five-Year Plan.

In more than 20 years of business practice, the company adheres to the core values ​​of "being good and doing good, doing right and doing right", spontaneously and consciously practices corporate social responsibility, always maintains the good intentions of motivation and intention, and volunteers to maintain the natural and social ecology. Sympathy and prosperity have formed a unique and sustainable development system. As of the end of 2022, the company has invested a total of 150.1 million yuan in medical care, education, rural revitalization, and donations for the "new crown" epidemic prevention and control in Tibet and the west.

Since its listing, the company has always focused on its main business and maintained steady and continuous growth in its performance. In 2022, the company achieved operating income of 2.045 billion yuan, a year-on-year increase of 15.49%; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 440 million yuan, a year-on-year increase of 27.57%.